Journal of Medical-Clinical Research Review, cilt.5, sa.2, ss.1-16, 2021 (ESCI İndekslerine Giren Dergi)
We highlight the composition and function of exosomes produced during cancer disease
in our work, how these vesicles could function as carriers of the RNA-peptide molecule. Finally, according to
the algorithms CRUZ RODRIGUEZ (CR) we are proposing various methods to develop a novel vaccine against
breast, ovarian, and lung cancers. Therefore, six RNA-peptides from our previous study were chosen based on
the potential of inducing strong fusion stability (FS=58.50 cruz) and exosome affinity (EA=59.80 ro), Biological
Action (BA= 1.0223 ro/cruz). This result may lead to the development of promising new therapeutic approaches
in cancer management by using exosome-mediated miRNA-peptide vaccine therapy. Due to, according to the
algorithm CR the Optimal Biological Action (OBA) value for antitumoral RNA-peptide with Exosome as carrier
are: 0.8 < OBA < 1.3. These results suggest that the designed vaccine can elicit specific immune responses against
three types of cancer; however, these results need experimental studies to confirm the efficacy and safety profile of
the proposed vaccine structure.